NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients is currently closed and not accepting new applications. This program previously helped patients pay for medications and treatment costs related to this serious muscle disease. You can check the PAN Foundation website to see when the program reopens or explore other financial assistance options.
WHY IT MATTERSIf you have Duchenne muscular dystrophy and need help paying for medications or treatments, you'll need to find alternative financial assistance programs since this particular fund is not currently accepting applications.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and not accepting new applications. Hereditary angioedema is a rare genetic condition that causes sudden swelling in the face, throat, hands, feet, and digestive system. Patients who need help paying for HAE treatment should check back at the foundation's website or contact them directly to learn when the program might reopen.
WHY IT MATTERSIf you have hereditary angioedema and struggle to afford medications or treatment, this closed fund means you'll need to explore alternative financial assistance programs or payment plans with your healthcare provider right now.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for cystic fibrosis patients is currently closed and not accepting new applications. This program helps patients pay for CF medications and treatments. You can check the PAN Foundation website to see when the fund reopens or to get on a waitlist.
WHY IT MATTERSIf you have cystic fibrosis and struggle to afford your medications, you'll need to find alternative financial assistance programs or contact your healthcare provider about other options while this fund is closed.
ResearchPUBMEDApr 20
Researchers in New Zealand interviewed 15 people with rare diseases and their caregivers to understand what it's like to get diagnosed and treated. They found that patients often have to fight hard to get answers and support because doctors don't know much about rare diseases. The study shows that people with rare diseases face similar challenges, even though their specific conditions are very different.
WHY IT MATTERSThis research directly documents the real-world barriers that rare disease patients face in accessing diagnosis and care in New Zealand, providing evidence that could help healthcare systems improve support for the estimated 300 million people worldwide living with rare disorders.
Clinical trialCLINICALTRIALSApr 20
Researchers are looking for adults and children with certain immune system disorders to join a study. The immune system normally helps your body fight infections, but in some people it doesn't work properly, causing frequent infections and other health problems. This study wants to understand why some immune systems fail and how to help people with these conditions. Relatives of affected people may also be able to join.
WHY IT MATTERSThis trial is actively recruiting 500 participants with four specific genetic immune disorders (PI3KCD, CTLA4, STAT3GOF, and MAGT1 deficiency) — if you or a family member has one of these diagnoses, you may be eligible to enroll now and contribute to understanding these rare conditions.
Clinical trialCLINICALTRIALSApr 20
Williams syndrome is a rare genetic condition that affects about 1 in every 8,000 to 12,000 people. It happens when a person is missing a small section of DNA on chromosome 7, which includes the gene that makes elastin (a protein that helps blood vessels stretch). This causes distinctive facial features and heart and blood vessel problems. Researchers are now recruiting 1,099 people with Williams syndrome or a related heart condition called supravalvular aortic stenosis to donate DNA and tissue samples to help scientists better understand these conditions.
WHY IT MATTERSThis actively recruiting biobank offers Williams syndrome and SVAS patients a direct way to contribute DNA and tissue samples to NHLBI-sponsored research that could accelerate understanding of the genetic causes and lead to new treatments.
PolicyRSSApr 20
The FDA announced it has completed its first year of goals to reduce the use of animals in drug testing. The agency launched several new programs to replace animal testing with alternative methods that are often faster and more accurate. This shift means new medicines can be developed and tested in ways that don't require testing on animals.
WHY IT MATTERSFaster, more reliable drug testing methods could accelerate the development and approval of treatments for rare diseases, potentially bringing new therapies to patients years sooner than traditional animal testing timelines allow.
ResearchBIORXIVApr 20
Researchers analyzed blood samples from over 5,400 people with rare genetic diseases to see if a test called RNA-Seq could help find the genetic cause of their conditions. They found that this blood test works better for some diseases than others, and they used special computer programs to spot unusual gene activity patterns that might explain why people got sick. This study shows that blood tests could be a useful tool to help diagnose rare diseases alongside other genetic tests.
WHY IT MATTERSIf you have an undiagnosed rare disease, this research suggests blood-based RNA testing could help identify the genetic cause—potentially leading to a diagnosis after years of searching.
ResearchBIORXIVApr 20
Researchers studied blood samples from children with dengue virus infection to find early warning signs that could predict who will develop severe disease. By analyzing proteins in the blood, they identified markers related to inflammation and blood vessel damage that appear in children who get sicker. This discovery could help doctors quickly identify which children need more intensive care.
WHY IT MATTERSIf validated, these protein markers could enable doctors to predict dengue severity within hours of diagnosis in children, allowing earlier intervention before complications like hemorrhagic fever or shock develop.
ResearchBIORXIVApr 18
Researchers studied blood proteins in over 2,400 older adults to find which ones might predict memory and thinking problems later in life. They found 34 proteins linked to faster decline in orientation (knowing where you are and what time it is) and 18 proteins linked to memory loss over 15 years. This early-stage research could help doctors identify people at risk for dementia before symptoms appear.
WHY IT MATTERSIf validated, these protein signatures could enable blood tests to identify people at risk for cognitive decline years before symptoms develop, potentially opening windows for preventive treatments in Alzheimer's disease and related dementias.
ResearchCLINICALTRIALSApr 17
Researchers completed a study that collected information about how Canavan disease develops and progresses in children. The study looked at medical records from 67 patients and also gathered new information about their movement abilities and important health milestones. This type of study helps doctors understand the disease better and can guide future treatment development.
WHY IT MATTERSThis completed natural history study provides detailed data on how Canavan disease progresses in children, which is essential for designing future clinical trials and understanding what to expect from the disease.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called SPK-10001 to treat Huntington's disease, a rare brain disorder that causes movement problems and cognitive decline. This early-stage study will check if the treatment is safe and whether it helps patients. About 53 people with Huntington's disease will participate in this trial, which is being run by Roche, a major pharmaceutical company.
WHY IT MATTERSThis is one of the first human trials of SPK-10001, a gene therapy specifically designed to target the genetic cause of Huntington's disease, offering hope for a disease that currently has no cure.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called BBP-812 to treat Canavan disease, a rare brain disorder that affects children. The therapy uses a modified virus to deliver a healthy copy of a gene that's missing or broken in people with this disease. This early-stage trial will check if the treatment is safe and whether it helps patients.
WHY IT MATTERSThis trial is now actively recruiting children with Canavan disease — if your child has been diagnosed, you may be eligible to participate in one of the first human tests of this gene therapy approach.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new treatment called IFx-Hu2.0 combined with a cancer drug called pembrolizumab for people with Merkel cell carcinoma, a rare and aggressive skin cancer. In this study, some patients will receive the new treatment while others receive a placebo (fake treatment) to see which works better. The trial is looking for 118 adults to participate and is currently accepting new patients.
WHY IT MATTERSThis is the first Phase 2/3 trial testing IFx-Hu2.0 as an add-on therapy for Merkel cell carcinoma, offering checkpoint inhibitor-naïve patients a potential new treatment option beyond standard pembrolizumab alone.
ResearchPUBMEDApr 17
Researchers in Saudi Arabia studied how different factors affect the stress and well-being of parents who have children with three rare genetic diseases: cystic fibrosis, congenital adrenal hyperplasia, and Duchenne muscular dystrophy. They surveyed 107 parents and found that things like whether parents work, family income, and cultural factors all play a role in how well parents cope with having a sick child. Understanding these factors can help doctors and support services better help families dealing with rare diseases.
WHY IT MATTERSIf you're a parent of a child with CF, CAH, or DMD, this research identifies specific factors affecting your quality of life—such as employment status and family support—that healthcare providers can now address to improve your family's well-being.
ResearchBIORXIVApr 17
Scientists created OpenScientist, a new artificial intelligence tool that can help researchers discover medical breakthroughs faster. This AI assistant can read through lots of medical information, analyze data, and put together what it learns — tasks that normally take human scientists a long time. The goal is to speed up finding new treatments and understanding diseases better.
WHY IT MATTERSThis AI tool could help researchers discover new treatments and understand rare diseases more quickly by automating time-consuming research tasks, potentially leading to faster development of therapies for patients with rare conditions.
ResearchBIORXIVApr 17
Scientists are testing a new way to understand how genes cause diseases by combining two different research methods: one that studies genes in large groups of people, and another that looks at individual cells in the lab. This study checks whether both methods give the same answers, which would help researchers trust their findings more and move treatments from the lab to real patients faster.
WHY IT MATTERSIf validated, this approach could accelerate how researchers identify disease-causing genes in rheumatologic conditions, potentially leading to faster development of targeted treatments for patients with autoimmune and inflammatory diseases.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
ResearchBIORXIVApr 16
Researchers found that a protein called DDR2 is overactive in Alzheimer's disease and may be blocking the brain's natural cleaning system. They developed an antibody (a type of immune protein) that can cross into the brain and reduce DDR2 levels, which in early studies helped restore the brain's ability to clear out harmful waste products and improved Alzheimer's symptoms in animal models.
WHY IT MATTERSThis research identifies a new therapeutic target for Alzheimer's disease that works through a different mechanism than current treatments, potentially offering hope for patients whose disease progresses despite existing amyloid-targeting therapies.
ResearchPUBMEDApr 16
Scientists created a new tool called STRIPE that uses advanced genetic testing to read long strands of RNA (the instructions cells use to make proteins). This tool can detect genetic mistakes that cause rare diseases by looking at how genes are actually working in cells, not just finding the mutations themselves. It's designed to be faster, cheaper, and more practical than older methods, which could help doctors diagnose rare genetic diseases that are hard to identify.
WHY IT MATTERSPatients with undiagnosed rare genetic diseases could finally get answers through more accurate genetic testing, since STRIPE can detect disease-causing variants that standard DNA tests might miss.